Welcome to LookChem.com Sign In|Join Free

CAS

  • or

149934-16-7

Post Buying Request

149934-16-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

149934-16-7 Usage

Description

[4S-(4α,4aα,5aα,12aα)]-4,7-Bis(diMethylaMino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxaMide is a complex organic compound with a unique molecular structure. It is characterized by its octahydro-naphthoquinone core, which is substituted with various functional groups, including diMethylaMino, hydroxy, and nitro groups. [4S-(4α,4aα,5aα,12aα)]-4,7-Bis(diMethylaMino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxaMide exhibits a range of biological activities and has potential applications in various fields due to its unique chemical properties.

Uses

1. Used in Pharmaceutical Applications:
[4S-(4α,4aα,5aα,12aα)]-4,7-Bis(diMethylaMino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxaMide is used as a pharmaceutical agent for its potential therapeutic effects. The compound's unique structure and functional groups may allow it to interact with specific biological targets, making it a promising candidate for the development of new drugs.
2. Used in Chemical Synthesis:
[4S-(4α,4aα,5aα,12aα)]-4,7-Bis(diMethylaMino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxaMide can be used as a key intermediate or building block in the synthesis of other complex organic molecules. Its versatile structure and functional groups make it a valuable starting material for the preparation of various chemical compounds, including pharmaceuticals, dyes, and other specialty chemicals.
3. Used in Research and Development:
Due to its unique structure and potential biological activities, [4S-(4α,4aα,5aα,12aα)]-4,7-Bis(diMethylaMino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxaMide can be employed as a research tool in various scientific fields, such as medicinal chemistry, biochemistry, and pharmacology. It can be used to study the structure-activity relationships of related compounds and to investigate the mechanisms of action of potential drug candidates.
4. Used in Analytical Chemistry:
The compound's unique structure and functional groups may also make it useful as a reagent or analytical standard in various analytical techniques, such as chromatography, spectroscopy, and electrochemistry. It can be employed to develop new methods for the detection and quantification of specific analytes or to improve the sensitivity and selectivity of existing analytical procedures.

Indications

Minoxidil, an antihypertensive agent, produces arteriolar vasodilation by an unknown mechanism. In limited clinical studies, minoxidil increases penile rigidity and has been used in the long-term treatment of organic impotence.

Biological Functions

Minoxidil (Loniten) is an orally effective vasodilator. It is more potent and longer acting than hydralazine and does not accumulate significantly in patients with renal insufficiency. It depends on in vivo metabolism by hepatic enzymes to produce an active metabolite, minoxidil sulfate. Minoxidil sulfate activates potassium channels, resulting in hyperpolarization of vascular smooth muscle and relaxation of the blood vessel.

Pharmacology

The hemodynamic effects of minoxidil are generally similar to those of hydralazine, with the noteworthy exception that a greater decrease in peripheral vascular resistance and consequently a larger reduction in blood pressure can be achieved with minoxidil. Minoxidil produces no important changes in either renal blood flow or glomerular filtration rate. It has little or no effect on venous capacitance and does not inhibit the reflex activation of the sympathetic nervous system. Orthostasis and other side effects of sympathetic blockade are therefore not a problem. As with hydralazine, there is a significant increase in cardiac output that is secondary to reflex increases in sympathetic activity, hyperreninemia, and salt and water retention.These effects can substantially reduce the effectiveness of minoxidil when it is used alone.The addition of a -blocker and a diuretic to the therapeutic regimen will preserve minoxidil’s antihypertensive action while attenuating some of the undesirable side effects.

Clinical Use

The major indications for the use of minoxidil are (1) severe hypertension that may be life threatening and (2) hypertension that is resistant to milder forms of therapy. Compromises in renal function do not prolong either the plasma or the therapeutic half-life of minoxidil, and therefore, it seems to be particularly important for hypertensive patients with chronic renal failure.

Side effects

Signs of toxicity common to vasodilator therapy in general also occur with minoxidil; they are attributable to vasodilation and reflex increases in sympathetic nerve activity. These include headache, nasal congestion, tachycardia, and palpitations. These effects do not have great clinical importance, since minoxidil is almost always administered in combination with a -blocker, which antagonizes the indirect cardiac effects. A more troublesome side effect, particularly in women, is the growth of body hair, possibly due to a direct stimulation of the growth and maturation of cells that form hair shafts. Apparently, minoxidil activates a specific gene that regulates hair shaft protein. In any case, this particular side effect has been capitalized upon, and minoxidil is now marketed as Rogaine for the treatment of male pattern baldness.

Metabolism

Peak concentrations of minoxidil in the blood occur 1 hour after oral administration, although the therapeutic effect may take 2 or more hours to manifest. This is probably related to the time it takes to convert minoxidil to minoxidil sulfate. The antihypertensive action after an oral dose of minoxidil lasts 12 to 24 hours. The long duration of action allows the drug to be administered only once or twice a day, a regimen that may be beneficial for compliance. Interestingly, the therapeutic half-life is considerably longer than the plasma half-life. This may be, as has been suggested for hydralazine, a result either of accumulation of the drug and its active metabolite in arterial walls or a longer plasma half-life of the sulfated metabolite, or both. The ultimate disposition of minoxidil depends primarily on hepatic metabolism and only slightly on renal excretion of unchanged drug. Because of this, pharmacological activity is not cumulative in patients with renal failure.

Check Digit Verification of cas no

The CAS Registry Mumber 149934-16-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,9,9,3 and 4 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 149934-16:
(8*1)+(7*4)+(6*9)+(5*9)+(4*3)+(3*4)+(2*1)+(1*6)=167
167 % 10 = 7
So 149934-16-7 is a valid CAS Registry Number.

149934-16-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name (4S,4aS,5aR,12S)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxanaphthacene-2-carboxamide

1.2 Other means of identification

Product number -
Other names 9-NITRO MINOCYCLINE

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:149934-16-7 SDS

149934-16-7Relevant articles and documents

Synthesis and antibacterial activity of 9-substituted minocycline derivatives

Sum, Phaik-Eng,Ross, Adma T.,Petersen, Peter J.,Testa, Raymond T.

, p. 400 - 403 (2006)

A number of 9-acylamino and 9-sulfonylamino derivatives of minocycline have been synthesized for structure-activity relationship studies. These compounds showed activity against both tetracycline-susceptible and tetracycline-resistant strains. Many of the

An improved process for the preparation of Tigecycline intermediate and process for the preparation of Tigecycline therefrom

-

Page/Page column 12-13, (2022/02/15)

The present invention relates to a process for the preparation of Tigecycline intermediate i.e. 9-amino minocycline of formula-1(C). More particularly, the present invention relates to a process for the preparation of 9-amino minocycline of formula 1(C) and a process for the preparation of Tigecycline of formula 1 from 9-nitro minocycline of formula 1(B).

Isolation of tetracycline derivatives

-

Page/Page column 2-3, (2008/06/13)

Provided is a process for the isolation of tetracycline derivatives.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 149934-16-7